Abstract

PURPOSE:

Erectile dysfunction is a common problem, particularly in diabetics. It is associated with a considerable burden of suffering. No generally accepted drug treatment exists. We systematically reviewed and meta-analyzed all randomized, placebo-controlled trials of yohimbine monotherapy for erectile dysfunction to determine its therapeutic efficacy. Our secondary aim was to evaluate the safety of yohimbine.

MATERIALS AND METHODS:

We used computerized literature searches and standardized data extraction to rate methodological quality in a meta-analysis using computer statistical software.

RESULTS:

Seven trials fit the predefined inclusion criteria. The overall methodological quality of these studies was satisfactory. The meta-analysis demonstrated that yohimbine is superior to placebo in the treatment of erectile dysfunction (odds ratio 3.85, 95% confidence interval 6.67 to 2.22). Serious adverse reactions were infrequent and reversible.

Does Yohimbine Help with Erections?

Yohimbine is thought to help alleviate erectile dysfunction by blocking the receptors responsible for preventing erections. Yohimbine may also promote the release of nitric oxide. This could lead to the dilation of blood vessels and an increase in blood flow to sexual organs.

CONCLUSIONS:

The benefit of Yohimbine medication for erectile dysfunction seems to outweigh its risks. Therefore, yohimbine is believed to be a reasonable therapeutic option for erectile dysfunction that should be considered as an initial pharmacological intervention.

The post Yohimbine for Erectile Dysfunction appeared first on Stanford Chemicals.